B-cell directed therapies in antiphospholipid antibody syndrome — New directions based on murine and human data
Authors:
- Saakshi KhattriSKSaakshi Khattri
- Gisele Zandman-GoddardGZGisele Zandman-Goddard
- Elena PeevaEPElena Peeva
- 1 August 2012
- journal article
- review article
- Published by Elsevier in Autoimmunity Reviews
- Vol. 11 (10) , 717-722
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Effects of Antiphospholipid Antibodies on In Vitro Platelet AggregationClinical and Applied Thrombosis/Hemostasis, 2011
- Rituximab therapy for autoimmune haematological diseasesEuropean Journal of Internal Medicine, 2011
- Antiphospholipid antibodies: Paradigm in transitionJournal of Neuroinflammation, 2009
- Prevention of murine antiphospholipid syndrome by BAFF blockadeArthritis & Rheumatism, 2008
- Antiphospholipid Antibodies and the Antiphospholipid Syndrome: Pathogenic MechanismsSeminars in Thrombosis and Hemostasis, 2008
- Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literatureLupus, 2008
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Rituximab therapy for multisystem autoimmune diseases in pediatric patientsThe Journal of Pediatrics, 2003
- Immunization of naive BALB/c mice with human β2‐Glycoprotein I breaks tolerance to the murine moleculeArthritis & Rheumatism, 2002
- Immunology of the antiphospholipid antibody syndromeArthritis & Rheumatism, 1996